Tuesday’s Pre-Market Look: Stocks In The News Before The Open

ByGary Kaltbaum

Biogen (BIIB) is up 1% in pre-market trading after it was upgraded to a ‘Buy’ at Citigroup with a price target of $305.

Sysco (SYY) was upgraded to ‘Outperform’ from ‘Neutral’ at Credit Suisse with a price target of $59.

Twenty-First Century Fox (FOXA) gained 1% in after-hours trading after it reported Q2 adjusted EPS continuing operations of 53 cents, higher than consensus of 49 cents.

FMC Corp. (FMC) fell nearly 5% in after-hours trading after it reported Q4 revenue of $865.6 million, below consensus of $916.1 million.

The Gap (GPS) rose 3% in after-hours trading after it said it sees Q4 adjusted EPS of 50 cents-51 cents, above consensus of 45 cents.

Allison Transmission Holdings (ALSN) rallied 5% in after-hours trading after it said it will buy back all ValueAct’s holdings in the company at $34.50 a share.

HealthEquity (HQY) lost over 5% in after-hours trading after it forecast preliminary 2017 EPS of 38 cents-42 cents, below consensus of 42 cents.

Fabrinet (FN) climbed over 3% in after-hours trading after it reported Q2 adjusted EPS of 91 cents, better than consensus of 79 cents, and then said it sees Q3 revenue of $360 million-$364 million, higher than consensus of $334.7 million.

YRC Worldwide (YRCW) dropped 4% in after-hours trading after it reported a Q4 loss of -23 cents, a wider loss than consensus of -12 cents.

Teva Pharmaceutical (TEVA) lost nearly 1% in after-hours trading after CEO Erez Vigodman was said to step down immediately.

Houlihan Lokey (HLI) slid nearly 2% in after-hours trading after it announced a primary offering of 10 million shares of Class A common stock.

Luminex (LMNX) fell 2% in after-hours trading after it reported Q4 adjusted EPS of 11 cents, weaker than consensus of 18 cents.

Cellectis SA (CLLS) climbed nearly 5% in after-hours trading after it received an Investigational New Drug (IND) approval from the FDA to conduct a Phase 1 trial with its UCART123 in patients with acute leukemia and blastic plasmacytoid dendreitic cell neoplasm.

Antero Midstream Partners LP (AM) slid 3% in after-hours trading after it launched a public offering of 5-million common units.

Source: FoxBusiness, Barchart, Bloomberg, Reuters